Dr. Robert Spiera, MD
Claim this profileHospital for Special Surgery
Studies Systemic Sclerosis
Studies Scleroderma
6 reported clinical trials
9 drugs studied
Affiliated Hospitals
Clinical Trials Robert Spiera, MD is currently running
Belimumab + Rituximab
for Systemic Sclerosis
This is a 52 week, single center, randomized, double-blind, placebo-controlled study. After patients maintain a stable dose of Mycophenolate Mofetil (MMF) for at least 1 month, they will be randomized to treatment with either Belimumab \& Rituximab or placebo.Patients in both groups will be on background MMF for the entirety of the study. Belimumab will be administered subcutaneously and Rituximab intravenously. Placebo injections and infusions will be of normal saline. Randomization will be done in a 2:1 manner to favor the treatment group. It is hypothesized that that Rituximab and Belimumab combination therapy with Mycophenolate Mofetil background therapy will improve fibrosis in SSc skin when compared to treatment with placebo and Mycophenolate Mofetil in a group of patients with early dcSSc.
Recruiting0 awards Phase 25 criteria
Abatacept
for Giant Cell Arteritis
This randomized, double-blind, placebo-controlled trial will seek to determine the efficacy of abatacept in GCA. To examine this objective, 62 eligible patients who have newly diagnosed or relapsing GCA within 8 weeks prior to screening will be randomized at a 1:1 ratio to receive subcutaneous abatacept 125mg/week or placebo. Patients who achieve remission will remain on their blinded assignment for 12 months at which time abatacept/placebo will be stopped. Patients who do not achieve remission by Month 3, who experience a relapse within the first 12 months will have the option of receiving open-label abatacept for a maximum of 12 months.
Recruiting1 award Phase 36 criteria
More about Robert Spiera, MD
Clinical Trial Related6 years of experience running clinical trials · Led 6 trials as a Principal Investigator · 4 Active Clinical TrialsTreatments Robert Spiera, MD has experience with
- Belimumab
- Placebo
- MMF
- Placebo Infusion
- Placebo Subcutaneous Injection
- Rituximab
Breakdown of trials Robert Spiera, MD has run
Systemic Sclerosis
Scleroderma
Systemic Scleroderma
Multiple sclerosis
Arteritis
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Robert Spiera, MD specialize in?
Robert Spiera, MD focuses on Systemic Sclerosis and Scleroderma. In particular, much of their work with Systemic Sclerosis has involved treating patients, or patients who are undergoing treatment.
Is Robert Spiera, MD currently recruiting for clinical trials?
Yes, Robert Spiera, MD is currently recruiting for 4 clinical trials in New York New York. If you're interested in participating, you should apply.
Are there any treatments that Robert Spiera, MD has studied deeply?
Yes, Robert Spiera, MD has studied treatments such as Belimumab, Placebo, MMF.
What is the best way to schedule an appointment with Robert Spiera, MD?
Apply for one of the trials that Robert Spiera, MD is conducting.
What is the office address of Robert Spiera, MD?
The office of Robert Spiera, MD is located at: Hospital for Special Surgery, New York, New York 10021 United States. This is the address for their practice at the Hospital for Special Surgery.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.